Filing Details

Accession Number:
0000899243-18-017071
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-06-18 18:56:39
Reporting Period:
2018-06-14
Accepted Time:
2018-06-18 18:56:39
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1062822 Lexicon Pharmaceuticals Inc. LXRX () N4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1053906 S.a. Group Artal Valley Park, 44, Rue De La Vallee
Luxembourg N4 L-2661
Yes No Yes No
1218180 S.c.a. International Artal Valley Park, 44, Rue De La Vallee
Luxembourg N4 L-2661
Yes No Yes No
1283968 S.a. Westend Valley Park, 44, Rue De La Vallee
Luxembourg N4 L-2661
Yes No Yes No
1340096 Invus Public Equities Advisors, Llc 750 Lexington Avenue, 30Th Floor
New York NY 10022
Yes No Yes No
1340097 Invus Public Equities, L.p. 750 Lexington Avenue, 30Th Floor
New York NY 10022
Yes No Yes No
1404553 Invus Advisors, L.l.c. 750 Lexington Avenue, 30Th Floor
New York NY 10022
Yes No Yes No
1404570 Invus, L.p. 750 Lexington Avenue, 30Th Floor
New York NY 10022
Yes No Yes No
1460839 Pascal Minne Rue De L'Industrie 44
Bruxelles C9 B-1000
Yes No Yes No
1460840 Westend Administratiekantoor Stichting Ijsselburcht 3
Arnhem P7 NL-6825 BS
Yes No Yes No
1522131 S.a. Management International Artal Valley Park, 44, Rue De La Vallee
Luxembourg N4 L-2661
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-06-14 9,200 $12.66 2,970,094 No 4 P Indirect See Footnotes
Common Stock Acquisiton 2018-06-18 36,584 $13.06 3,006,678 No 4 P Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnotes
No 4 P Indirect See Footnotes
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 21,321,961 Indirect See Footnotes
Common Stock 35,402,689 Indirect See Footnotes
Footnotes
  1. The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").
  2. The shares reported as purchased on June 14, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.575 to $12.79 per share and the shares reported as purchased on June 18, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.95 to $13.10 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
  3. These securities are directly held by Invus Public Equities, L.P.
  4. These securities are directly held by Artal International S.C.A.
  5. These securities are directly held by Invus, L.P.
  6. Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.
  7. Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.